Performance of transrectal prostate biopsies in detecting tumours and implications for focal therapy

References

• Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011;364:1708–17.
   PubMed Web of Science ®Google Scholar
• Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, et al. Radical Prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012;367:203–13.
   PubMed Web of Science ®Google Scholar
• Boyd LK, Mao X, Xue L, Lin D, Chaplin T, Kudahetti SC, et al. High-resolution genome-wide copy-number analysis suggests a monoclonal origin of multifocal prostate cancer. Genes Chromosomes Cancer 2012;51:579–89.
   Google Scholar
• Liu W, Laitinen S, Khan S, Vihinen M, Kowalski J, Yu G, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559–65.
   PubMed Web of Science ®Google Scholar
• Woodfield CA, Tung GA, Grand DJ, Pezzullo JA, Machan JT, Renzulli JF. Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. AJR Am J Roentgenol 2010;194:W316–22.
   PubMed Web of Science ®Google Scholar
• Vasarainen H, Lahdensuo K, Savolainen R, Ruutu M, Taari K, Rannikko A. Diffusion-weighted magnetic resonance imaging in prostate cancer patients on active surveillance one year after diagnosis and before repeat biopsy. Scand J Urol 2013;47:456–61.
   PubMed Web of Science ®Google Scholar
• Guzzo TJ, Resnick MJ, Canter DJ, Bivalacqua TJ, Rosen MA, Bergey MR, et al. Endorectal T2-weighted MRI does not differentiate between favorable and adverse pathologic features in men with prostate cancer who would qualify for active surveillance. Urol Oncol 2012;30:301–5.
   PubMedGoogle Scholar
• Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling. Mod Pathol 2011;24:6–15.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent – update 2013. Eur Urol 2014;65:124–37.
   PubMed Web of Science ®Google Scholar
• Barret E, Ahallal Y, Sanchez-Salas R, Galiano M, Cosset JM, Validire P, et al. Morbidity of focal therapy in the treatment of localized prostate cancer. Eur Urol 2013;63:618–22.
   PubMed Web of Science ®Google Scholar
• Ahmed HU, Freeman A, Kirkham A, Sahu M, Scott R, Allen C, et al. Focal therapy for localized prostate cancer: a phase I/II trial. J Urol 2011;185:1246–54.
   PubMedGoogle Scholar
• De Laet K, De La Taille A, Ploussard G, Hoznek A, Vordos D, Yiou R, et al. Predicting tumour location in radical prostatectomy specimens: same-patient comparisons of 21-sample versus sextant biopsy. BJU Int 2009;104:616–20.
   Google Scholar
• Iremashvili V, Pelaez L, Jorda M, Manoharan M, Arianayagam M, Rosenberg DL, et al. Prostate sampling by 12-core biopsy: comparison of the biopsy results with tumor location in prostatectomy specimens. Urology 2012;79:37–42.
   PubMed Web of Science ®Google Scholar
• Schulte RT, Wood DP, Daignault S, Shah RB, Wei JT. Utility of extended pattern prostate biopsies for tumor localization: pathologic correlations after radical prostatectomy. Cancer 2008;113:1559–65.
   PubMed Web of Science ®Google Scholar
• Washington SL, Bonham M, Whitson JM, Cowan JE, Carroll PR. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int 2012;110:50–5.
   Google Scholar
• Tseng KS, Landis P, Brimo F, Partin AW, Epstein JI, Carter HB. Repeat prostate biopsies predict location of index cancer in an active surveillance cohort. BJU Int 2011;108:1415–20.
   Google Scholar
• van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24:16–25.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Scattoni V, Raber M, Roscigno M, Briganti A, Suardi N, et al. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. BJU Int 2011;108:366–71.
   Google Scholar
• Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, et al. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. BJU Int 2012;110:E64–8.
   Google Scholar
• Karavitakis M, Winkler M, Abel P, Livni N, Beckley I, Ahmed HU. Histological characteristics of the index lesion in whole-mount radical prostatectomy specimens: implications for focal therapy. Prostate Cancer Prostatic Dis 2011;14:46–52.
   PubMed Web of Science ®Google Scholar
• Bott SR, Ahmed HU, Hindley RG, Abdul-Rahman A, Freeman A, Emberton M. The index lesion and focal therapy: an analysis of the pathological characteristics of prostate cancer. BJU Int 2010;106:1607–11.
   PubMed Web of Science ®Google Scholar
• Singh PB, Anele C, Dalton E, Barbouti O, Stevens D, Gurung P, et al. Prostate cancer tumour features on template prostate-mapping biopsies: implications for focal therapy. Eur Urol 2014;66:12–19.
   Google Scholar
• Karavitakis M, Ahmed HU, Abel PD, Hazell S, Winkler MH. Anatomically versus biologically unifocal prostate cancer: a pathological evaluation in the context of focal therapy. Ther Adv Urol 2012;4:155–60.
   Google Scholar
• Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869–75.
   PubMed Web of Science ®Google Scholar
• Bolenz C, Gierth M, Grobholz R, Kopke T, Semjonow A, Weiss C, et al. Clinical staging error in prostate cancer: localization and relevance of undetected tumour areas. BJU Int 2009;103:1184–9.
   Google Scholar
• Zaytoun OM, Jones JS. Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. Int J Urol 2011;18:557–68.
   PubMed Web of Science ®Google Scholar
• Pinto PA, Chung PH, Rastinehad AR, Baccala AAJr, Kruecker J, Benjamin CJ, et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. J Urol 2011;186:1281–5.
   PubMed Web of Science ®Google Scholar
• Walz J, Marcy M, Pianna JT, Brunelle S, Gravis G, Salem N, et al. Identification of the prostate cancer index lesion by real-time elastography: considerations for focal therapy of prostate cancer. World J Urol 2011;29:589–94.
   Google Scholar
• Yakar D, Schouten MG, Bosboom DG, Barentsz JO, Scheenen TW, Futterer JJ. Feasibility of a pneumatically actuated MR-compatible robot for transrectal prostate biopsy guidance. Radiology 2011;260:241–7.
   PubMed Web of Science ®Google Scholar
• Galosi AB, Muzzonigro G, Lacetera V, Mazzucchelli R. Specimen orientation by marking the peripheral end: (potential) clinical advantages in prostate biopsy. Prostate Cancer 2011;2011:270403.
   Google Scholar